|
|
|
|
|
Legal status
Patent lapsed (non-payment of fees)
| (51) | INT.CL. | A61K 31/485 | (2006.01) |
| A61P 25/24 | (2006.01) | ||
| A61P 25/04 | (2006.01) |
| (11) | Number of the document | 3153171 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16201359.3 |
| Date of filing the European patent application | 2012-12-14 | |
| (97) | Date of publication of the European application | 2017-04-12 |
| (45) | Date of publication and mention of the grant of the patent | 2018-09-19 |
| (46) | Date of publication of the claims translation | 2018-12-10 |
| (30) | Number | Date | Country code |
| 201161576233 P | 2011-12-15 | US |
| (72) |
DEAVER, Daniel, US
EHRICH, Elliott, US
|
| (73) |
Alkermes Pharma Ireland Limited,
Connaught House 1 Burlington Road, Dublin 4,
IE
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Samidorfanas (ALKS 33) derinyje su buprenorfinu, skirtas depresinių sutrikimų gydymui |
| SAMIDORPHAN (ALKS 33) IN COMBINATION WITH BUPRENORPHINE FOR THE TREATMENT OF DEPRESSIVE DISORDERS |
| Payment date | Validity (years) | Amount | |
| 2022-11-21 | 11 | 289.00 EUR |
| Patent lapsed (non-payment of fees) | ||
| Invalidation date | 2023-12-14 |